MREO Company Profile and Key Details

Q: Who are the executives of MREO?

Dr. Suba KrishnanSenior Vice President of Clinical Devel.Dr. Alastair MacKinnon M.D., MBBSCo-Founder and Chief of Portfolio & Pipeline StrategyMs. Christine Fox CPAChief Financial OfficerDr. Fiona BorHead of Intellectual PropertyDr. John P. Richard M.B.A., MBACo-Founder & Chief Bus. OfficerDr. Denise Scots-Knight Ph.D.Co-Founder, Chief Executive Officer & Executive DirectorMs. Alexandra Hughes-WilsonChief of Patient Access & Commercial PlanningDr. John A. Lewicki Ph.D.Chief Scientific OfficerDr. Jackie ParkinSenior Vice President & Therapeutic HeadDr. Arun MistryTherapeutic Area Head of SetrusumabDr. Ann Kapoun Ph.D.Senior Vice President of Translational R&DMr. Charles SermonCo-Founder, Gen. Counsel & Company Sec.

NASDAQ : MREO

Mereo BioPharma Group

$0.29

-2.0246-87.65%

At Close 4:00 PM

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Mereo BioPharma Group plc (MREO) stock declined over -87.65%, trading at $0.29 on NASDAQ, down from the previous close of $2.31. The stock opened at $0.25, fluctuating between $0.20 and $0.30 in the recent session.

Stock Snapshot

2.31

Prev. Close

45.57M

Market Cap

0.2

Day Low

-1.14

P/E Ratio

-0.25

EPS (TTM)

-0.22

Cash Flow per Share

0.25

Open

159.67M

Number of Shares

0.2985

Day High

83.03%

Free Float in %

0.37

Book Value

237.89M

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Dec 29, 2025	0.25	0.30	0.20	0.29	236.55M
Dec 26, 2025	2.27	2.34	2.27	2.31	838.99K
Dec 24, 2025	2.26	2.33	2.23	2.30	1.01M
Dec 23, 2025	2.29	2.33	2.22	2.29	1.75M
Dec 22, 2025	2.09	2.36	2.07	2.29	4.28M
Dec 19, 2025	2.00	2.12	1.97	2.00	2.58M
Dec 17, 2025	2.10	2.13	1.89	1.92	3.05M
Dec 16, 2025	2.18	2.19	2.10	2.10	1.9M
Dec 15, 2025	2.27	2.27	2.13	2.19	1.3M
Dec 12, 2025	2.21	2.31	2.17	2.17	2.21M
Dec 11, 2025	2.31	2.37	2.25	2.25	2.12M
Dec 10, 2025	2.18	2.33	2.13	2.31	2.57M
Dec 09, 2025	2.10	2.21	2.07	2.18	2.55M
Dec 08, 2025	2.10	2.23	2.02	2.13	2.38M
Dec 05, 2025	2.04	2.10	2.02	2.06	1.63M
Dec 04, 2025	1.95	2.06	1.90	2.04	2.36M
Dec 03, 2025	1.80	2.18	1.74	1.96	11.54M
Dec 02, 2025	1.85	1.85	1.75	1.75	1.06M
Dec 01, 2025	1.86	1.86	1.76	1.84	1.99M
Nov 28, 2025	1.85	1.89	1.81	1.87	602K

Contact Details

London, W1G 0QF

United Kingdom

https://www.mereobiopharma.com 443 330 237300

About Company

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), a novel antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 antitrypsin deficiency. The company has a collaboration with The University of Texas MD Anderson Cancer Center to evaluate anti-TIGIT therapeutic antibody candidate, etigilimab. Mereo BioPharma Group plc was incorporated in 2015 and is based in London, the United Kingdom.

Stock Peers

ARGX

-7.47-0.88%

argenx SE$837.45 REGN

-4.47-0.57%

Regeneron Pharmaceuticals, Inc.$780.50 MDGL

-9.44-1.58%

Madrigal Pharmaceuticals, Inc.$589.47 UTHR

-4.26-0.84%

United Therapeutics Corporation$502.90 VRTX

-3.12-0.67%

Vertex Pharmaceuticals Incorporated$459.78 ALNY

-1.77-0.44%

Alnylam Pharmaceuticals, Inc.$398.82 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 PRAX

35.63+13.25%

Praxis Precision Medicines, Inc.$304.58 KRYS

1.51+0.60%

Krystal Biotech, Inc.$253.68 SGEN

-0.16-0.07%

Seagen Inc.$228.74

Frequently Asked Questions

What is the current Mereo BioPharma Group plc (MREO) stock price?

Mereo BioPharma Group plc (NASDAQ: MREO) stock price is $0.29 in the last trading session. During the trading session, MREO stock reached the peak price of $0.30 while $0.20 was the lowest point it dropped to. The percentage change in MREO stock occurred in the recent session was -87.65% while the dollar amount for the price change in MREO stock was - $2.02.

MREO's industry and sector of operation?

The NASDAQ listed MREO is part of Biotechnology industry that operates in the broader Healthcare sector. Mereo BioPharma Group plc designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of MREO?

Dr. Suba Krishnan
Senior Vice President of Clinical Devel.
Dr. Alastair MacKinnon M.D., MBBS
Co-Founder and Chief of Portfolio & Pipeline Strategy
Ms. Christine Fox CPA
Chief Financial Officer
Dr. Fiona Bor
Head of Intellectual Property
Dr. John P. Richard M.B.A., MBA
Co-Founder & Chief Bus. Officer
Dr. Denise Scots-Knight Ph.D.
Co-Founder, Chief Executive Officer & Executive Director
Ms. Alexandra Hughes-Wilson
Chief of Patient Access & Commercial Planning
Dr. John A. Lewicki Ph.D.
Chief Scientific Officer
Dr. Jackie Parkin
Senior Vice President & Therapeutic Head
Dr. Arun Mistry
Therapeutic Area Head of Setrusumab
Dr. Ann Kapoun Ph.D.
Senior Vice President of Translational R&D
Mr. Charles Sermon
Co-Founder, Gen. Counsel & Company Sec.

How MREO did perform over past 52-week?

MREO's closing price is 42.7% higher than its 52-week low of $0.20 where as its distance from 52-week high of $3.84 is -92.57%.

How many employees does MREO have?

Number of MREO employees currently stands at 36.

Link for MREO official website?

Official Website of MREO is: https://www.mereobiopharma.com

How do I contact MREO?

MREO could be contacted at phone 443 330 237300 and can also be accessed through its website. MREO operates from One Cavendish Place, London, W1G 0QF, United Kingdom.

How many shares of MREO are traded daily?

MREO stock volume for the day was 237.89M shares. The average number of MREO shares traded daily for last 3 months was 1.86M.

What is the market cap of MREO currently?

The market value of MREO currently stands at $45.57M with its latest stock price at $0.29 and 159.67M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	36
Beta	0.38
Sales or Revenue	$10.00M
5Y Sales Change%	0%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

Employees	36
Beta	0.38
Sales or Revenue	$10.00M
5Y Sales Change%	0%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

MREO Company Profile and Key Details

Mereo BioPharma Group

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Frequently Asked Questions

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Company Overview

Technical Performance

Dividend & Fair Value

Financial & Profitability Overview

Quarterly Financial Highlights

Earnings & Analyst Outlook

Shareholding & Insider Activity

Valuation Metrics

Price Forecast & Outlook

Key Takeaways